A recent study led by Paul DeCaen, Ph.D., associate professor of Pharmacology, has identified novel molecular mechanisms by ...

Understanding the link between obesity, fatty liver disease and kidney stones provides a new perspective on prevention and ...

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...

The company raised $54.5 million to make treatments that restore protein function in polycystic kidney disease ...

The primary endpoint was functional immune tolerance, defined as off all immunosuppressive drugs 24 months after ...

A new research paper was published in Volume 16 of Oncotarget on June 25, 2025, titled "Hypoxia induced lipid droplet ...

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic ...

Internal medicine and rheumatology specialist Siobhan Deshauer, MD, does a deep dive on the signs of kidney disease. Following is a partial transcript of the video (note that errors are possible): ...

Landlords say no Company wants out of big biotech leases. Landlords say no How this Peninsula biotech plans to survive after ...

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

This new article publication from Acta Pharmaceutica Sinica B, discusses high intensity forced ultrasound-driven ferroptosis ...